Phillips Medisize, which completed its acquisition of inhalation CDMO Vectura in 2025, has announced the acquisition of all remaining portions of the former Vectura site in Chippenham, UK. The acquisition of Vectura originally included only part of that campus; Phillips Medisize will now own the entire 3.4 acres and approximately 59,000 sq m of facility space at the site.
According to Phillips Medisize, acquisition of the remaining parts of the Vectura campus will support its Global Inhalation Center of Excellence, which includes both Chippenham and Cambridge facilities and provides services for a wide range of OINDPs. The company says that the new acquisition will allow it to “broaden drug-device combination product formulation development for both early and late-phase clinical trial supplies manufacturing.”
Vectura announced in late 2020 that it would add a laboratory for handling highly potent APIs at the Chippenham facility, and in 2021, the company said that it was adding a new DPI filling and assembly line at the site. In 2022, Vectura announced plans for a 10,000 sq m Inhalation Centre of Excellence to be constructed at the Bristol & Bath Science Park.
Phillips Medisize VP of Inhalation Therapies Charlie Schumacher commented, “With our inhalation revenue projected to grow substantially over the next five years, securing this full site ensures we have the dedicated talent, laboratories, and cleanroom capacity required to support pharmaceutical companies from early-stage feasibility all the way through commercial scale-up. Since the Vectura acquisition, we are tracking ahead of schedule on our growth model and are confident in our trajectory. This expansion in Chippenham reinforces our momentum and ensures proven technical expertise and manufacturing continuity for our customers worldwide.”
Chief Inhalation Scientist Sandy Munro said, “We are deeply grateful for the overwhelming support and positive reception we continue to receive from our customers and the broader respiratory industry following the Vectura acquisition. Our team is absolutely delighted to be where we should be, back at industry conferences and on the podium sharing our latest research. We remain deeply committed to advancing the science in our field to bring more effective inhalation therapies to patients across the world, including those dealing with complex and challenging diseases like pulmonary arterial hypertension.”
Read the Phillips Medisize press release
